Creative Medical Technology Holdings Inc
NASDAQ:CELZ
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Creative Medical Technology Holdings Inc
NASDAQ:CELZ
|
4.6m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
395.1B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
204.9B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
190B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121.3B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.5B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87.4B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Creative Medical Technology Holdings Inc
Glance View
Creative Medical Technologies, Inc. develops novel regenerative medicine and stem cell technologies. The company is headquartered in Phoenix, Arizona. The company went IPO on 2009-05-01. The firm conducts its commercial operations through its subsidiary, Creative Medical Technologies, Inc. (CMT). CMT markets and sells its CaverStem and FemCelz disposable kits utilized by physicians to perform autologous procedures that treat erectile dysfunction and female sexual dysfunction and female sexual dysfunction, respectively. The firm's products include CaverStem, FemCelz, StemSpine, Amniostem, ImmCelz and OvaStem. CaverStem utilizes a patient's own stem cells to treat erectile dysfunction (ED). FemCelz is used for the treatment and procedure for vaginal rejuvenation function.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Creative Medical Technology Holdings Inc is 60%, which is above its 3-year median of 51.2%.
Over the last 3 years, Creative Medical Technology Holdings Inc’s Gross Margin has increased from 53.3% to 60%. During this period, it reached a low of 13.8% on Mar 31, 2024 and a high of 66.7% on Dec 31, 2022.
